Great session on evolving designs for #clinicaltrials in nephrology by Vlado Perkovic at GlomCon #Podocin A fitting end to the fellowship 🥳

Vasculitis encompasses a group of disorders characterized by inflammation of blood vessels with significant renal implications. This session will explore the pathology of small-vessel vasculitis, highlighting key histological findings, disease mechanisms, and diagnostic

Membranous nephropathy is a leading cause of adult nephrotic syndrome, characterized by immune complex deposition on the glomerular basement membrane. This session will cover the pathological features, diagnostic criteria, and underlying mechanisms of membranous nephropathy.

The one common denominator at today’s GlomCon graduation: PEOPLE. A celebration of life-long learners. Indeed a wonderful journey of seeing people achieving their dreams and potential. Cant wait to hear stories of how their learning will impact other lives.

Dr. Paolo Nikolai So Paolo Nikolai So Piedmont Athens Regional Medical Center GlomCon Instructor Social Media Committee Member at GlomCon Hawaii conference #GlomConHawaii #Experts #nephtwitter

1) The variable immunological and clinical course of MN with the hypothetical kidney role as a “immunological sink”

Invitation to apply for the GlomCon virtual fellowship by Fellowship director Kate Robson at #GlomConHawaii Wonderful opportunity for academia, mentorship, networking and friendship. #Podocin #Nephtwitter Closing date August 15th glomcon.org/fellowship

Membranous Nephropathy: Target Antigens ca. 2024 from Indian Journal of Nephrology Orhan Efe Paolo Nikolai So Urmila Anandh Nasim Wiegley, MD, FASN #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/38681023/

We are excited to announce the launch of GlomPedia 📖 The essential guide to glomerular diseases at your fingertips! GlomPedia is your go-to eBook library for diagnosing and managing glomerular diseases. 👉 Download it for free today on the Apple App Store and Google Play.

💡 Treatment strategies for severe ANCA vasculitis vary upon clinical presentation. 🎯Check out this beautiful VA by Paolo Nikolai So

People with CKD have a higher risk for progression to tuberculosis disease following infection with Mycobacterium tuberculosis. This study found that tuberculosis incidence among people with kidney failure between 2010 and 2021 in the United States was 10-fold that among people

New 🎙️: Drs. Agnès Boutet and Yasmine Lund-Ricard discuss a study that investigated the molecular properties of nephron progenitor cells (NPCs) within the kidney of the catshark (Scyliorhinus canicula). Molecular analysis of NPCs in a chondrichthyan species indicates that

#GlomPedia 🚨 UPDATE ALERT! Dive into the latest update of Membranous Nephropathy chapter ✨ by Drs. Orhan Efe , Paolo Nikolai So , Vanesa Bijol and Laura Mariani 👇

Anticoagulant-related nephropathy by Dr. Irene Martin, Dr. Paolo Nikolai So, Dr. Tiffany Caza and Dr. Mohamed Hassanein Read here 👉 pubs.glomcon.org/anticoagulant-… #GlomCon

Membranous Nephropathy: Treatment from Indian Journal of Nephrology GlomCon Nasim Wiegley, MD, FASN Urmila Anandh Paolo Nikolai So Orhan Efe #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/38681023/

APOL1 Mediated Kidney Disease (AMKD): Clinical approach to genetic testing ca. 2025 from Kidney Medicine GlomCon Edward Kwakyi Paolo Nikolai So Nasim Wiegley, MD, FASN #Nephpearls kidneymedicinejournal.org/article/S2590-…

Age can play an important role in how nephrologists treat individuals with glomerular diseases. This #ASNCJASN "How I Treat" article highlights key insights: kidney.pub/CJASN0805

APOL1 Mediated Kidney Disease (AMKD): Clinical approach to genetic testing ca. 2025 from Kidney Medicine GlomCon Edward Kwakyi Paolo Nikolai So Nasim Wiegley, MD, FASN #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/40837248/

Empowering the Next Generation of Nephrologists: Trainee Opportunities in #GlomCon's Educational Ecosystem ca. 2025 from ASN Publications GlomCon Nasim Wiegley, MD, FASN Harish Seethapathy Sayna Norouzi, MD, FASN Kate Robson Paolo Nikolai So Poyan Mehr #Nephpearls Graphic by Paolo Nikolai So 👉

1) Welcome to a new #accredited #tweetorial from @cardiomet_ce and @CKD_ce, addressing Phase 3 data from #ESC2025 on the first major advancement in #hypertension therapy in 20 years! We're talking about #aldosterone synthase inhibitors #ASI for difficult-to-control #HTN.